Trudel S, et al. - In patients with relapsed and refractory multiple myeloma, experts evaluated the safety, tolerability, and preliminary clinical activity of GSK2857916, a novel anti-B-cell maturation antigen (BCMA) antibody conjugated to microtubule-disrupting agent monomethyl auristatin F. At nine centers in the USA, Canada, and the UK, they conducted an international, multicentre, open-label, first-in-human phase 1 study with dose escalation (part 1) and dose expansion (part 2) phases. In heavily pretreated patients, a good tolerability and good clinical activity of GSK2857916 was seen at the identified recommended phase 2 dose. Thrombocytopenia and anemia were the most common grade 3 or 4 events.